Present the comprehensive evaluation methodology of the implementation Cameroon Email List of the Global Action Program to Overcome Mental Health Gaps (mhGAP) in Chile and present its results. Cross-sectional evaluative study based on a survey of key referents of the program, deployed in the 29 public health services of the country, and individual interviews and focus groups with key Cameroon Email List actors and experts. The focus of the evaluation was on the relevance and impact of mhGAP in the provision of mental health services and in the implementation of the program.
Participants positively evaluated the progressive implementation of Cameroon Email List in Chile, in particular: 1) they stated that they had better detection, diagnosis and treatment tools for common disorders, and efficient referral strategies; 2) they rated all modules as important; the most relevant were self-injury / Cameroon Email List suicide and mental and behavioral disorders of the child and adolescent they favorably evaluated the National Days and their replications and their contribution to the successful implementation of the MH GAP; 4) agreed on the need to incorporate new actors, strengthen some aspects, and expand information on the program.
Use of decisions of regulatory authorities of other jurisdictions
Describe the current status of the use Cameroon Email List of the decisions of regulatory authorities of other jurisdictions in Latin America and the Caribbean by evaluating national regulatory frameworks for the approval of new drugs and establishing foreign regulatory bodies that are considered reliable regulatory authorities for each country. The websites of regulatory Cameroon Email List authorities in Latin America and the Caribbean were searched to identify official regulations for the approval of new drugs. Data collection took place in December 2019 and was completed in June Cameroon Email List for the Caribbean countries. Two independent teams collected information on direct recognition or abbreviated procedures for the approval of new drugs and the reference regulatory authorities (trustworthy) thus defined in the corresponding national legislation.
Approve new medicinal products in Latin American and Caribbean countries
Regulatory documents on the approval of new products were found on the websites of twenty regulatory bodies in Latin America and the Caribbean, covering Cameroon Email List countries. Seven countries do not accept the use of decisions of foreign regulatory authorities. Thirteen regulatory authorities (Argentina, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala, Mexico, Panama, Paraguay, Peru, Dominican Republic, Uruguay and the single regulatory system for fifteen Caribbean States) explicitly agree to entrust decisions for approval of new drugs issued by the European Cameroon Email List Medicines Agency, the United States Food and Drug Administration and Health Canada. Ten countries also agree to use the marketing authorizations of Australia, Japan and Switzerland. Argentina Brazil,
The use of the decisions of regulatory Cameroon Email List authorities of other jurisdictions has become a common practice in Latin America and the Caribbean. Thirteen out of twenty regulatory authorities directly recognize or abbreviate the approval process for new drugs if they have previously received approval from a regulatory Cameroon Email List body in another jurisdiction. The European Medicines Agency, the Food and Drug Administration of the United States and Health Canada are the regulatory authorities of other jurisdictions in which the regulators of Latin America and the Caribbean trust more.